Targeting the p53 pathway

Vita M Golubovskaya; William G Cance

doi:10.1016/j.soc.2013.06.003

Targeting the p53 pathway

Surg Oncol Clin N Am. 2013 Oct;22(4):747-64. doi: 10.1016/j.soc.2013.06.003. Epub 2013 Jul 30.

Authors

Vita M Golubovskaya¹, William G Cance

Affiliation

¹ Department of Surgical Oncology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14127, USA; CureFAKtor Pharmaceuticals, 14 Rock Dove Lane, Orchard Park, Buffalo, NY 1427, USA.

Abstract

This article summarizes data on translational studies to target the p53 pathway in cancer. It describes the functions of the p53 and Mdm-2 signaling pathways, and discusses current therapeutic approaches to target p53 pathways, including reactivation of p53. In addition, direct interaction and colocalization of the p53 and focal adhesion kinase proteins in cancer cells have been demonstrated, and different approaches to target this interaction are reviewed. This is a broad review of p53 function as it relates to the diagnosis and treatment of a wide range of cancers.

Keywords: Apoptosis; FAK; Mdm-2; Survival; p53.

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Animals
Antineoplastic Agents / therapeutic use*
Humans
Molecular Targeted Therapy*
Neoplasms / drug therapy*
Signal Transduction / drug effects*
Tumor Suppressor Protein p53 / antagonists & inhibitors*

Substances

Antineoplastic Agents
Tumor Suppressor Protein p53

Abstract

Publication types

MeSH terms

Substances

Grants and funding